Literature DB >> 36118816

Thyroid Eye Disease.

Jason Szelog1, Hollister Swanson2, Matthew C Sniegowski3, David B Lyon4.   

Abstract

Thyroid eye disease, although rare, is the most common inflammatory orbital disorder and is associated with autoimmune thyroid dysfunction. It is a progressive disorder with symptoms and signs that may cause significant facial disfigurement, visual disability, but rarely blindness. We will review the diagnostic criteria, immunologic basis, clinical course, and medical and surgical treatments for thyroid eye disease. Recent developments in the use of biologic agents to treat this disorder appear to be changing its progression curve and offer the first specific and preventative therapeutic options. Copyright 2022 by the Missouri State Medical Association.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36118816      PMCID: PMC9462910     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  40 in total

1.  Genetic profiling in Graves' disease: further evidence for lack of a distinct genetic contribution to Graves' ophthalmopathy.

Authors:  Xiaoming Yin; Rauf Latif; Rebecca Bahn; Terry F Davies
Journal:  Thyroid       Date:  2012-06-04       Impact factor: 6.568

2.  Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.

Authors:  M P Mourits; M F Prummel; W M Wiersinga; L Koornneef
Journal:  Clin Endocrinol (Oxf)       Date:  1997-07       Impact factor: 3.478

3.  Childhood Graves' ophthalmopathy: results of a European questionnaire study.

Authors:  G E Krassas; M Segni; W M Wiersinga
Journal:  Eur J Endocrinol       Date:  2005-10       Impact factor: 6.664

4.  Transconjunctival Müller muscle recession with levator disinsertion for correction of eyelid retraction associated with thyroid-related orbitopathy.

Authors:  Guy J Ben Simon; Ahmad M Mansury; Robert M Schwarcz; Sara Modjtahedi; John D McCann; Robert A Goldberg
Journal:  Am J Ophthalmol       Date:  2005-07       Impact factor: 5.258

5.  A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.

Authors:  S D Lytton; K A Ponto; M Kanitz; N Matheis; L D Kohn; G J Kahaly
Journal:  J Clin Endocrinol Metab       Date:  2010-03-17       Impact factor: 5.958

Review 6.  Thyroid eye disease: what is new to know?

Authors:  Zhen Li; Dean M Cestari; Elizabeth Fortin
Journal:  Curr Opin Ophthalmol       Date:  2018-11       Impact factor: 3.761

7.  Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease.

Authors:  Joshua D Stein; David Childers; Shivani Gupta; Nidhi Talwar; Bin Nan; Brian J Lee; Terry J Smith; Raymond Douglas
Journal:  JAMA Ophthalmol       Date:  2015-03       Impact factor: 7.389

Review 8.  Thyroid eye disease: pathogenesis and treatment.

Authors:  Shameema Sikder; Robert S Weinberg
Journal:  Ophthalmologica       Date:  2009-11-24       Impact factor: 3.250

9.  Teprotumumab for the Treatment of Active Thyroid Eye Disease.

Authors:  Raymond S Douglas; George J Kahaly; Amy Patel; Saba Sile; Elizabeth H Z Thompson; Renee Perdok; James C Fleming; Brian T Fowler; Claudio Marcocci; Michele Marinò; Alessandro Antonelli; Roger Dailey; Gerald J Harris; Anja Eckstein; Jade Schiffman; Rosa Tang; Christine Nelson; Mario Salvi; Sara Wester; Jeffrey W Sherman; Thomas Vescio; Robert J Holt; Terry J Smith
Journal:  N Engl J Med       Date:  2020-01-23       Impact factor: 91.245

10.  Teprotumumab for the treatment of chronic thyroid eye disease.

Authors:  Shoaib Ugradar; Julia Kang; Andrea L Kossler; Erin Zimmerman; Jenna Braun; Andrew R Harrison; Swaraj Bose; Kimberly Cockerham; Raymond S Douglas
Journal:  Eye (Lond)       Date:  2021-07-09       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.